Trials / Withdrawn
WithdrawnNCT05451095
A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
A Randomized, Placebo Controlled, Double-blind, Double-dummy, Three-way Crossover Trial to Investigate the Effect of Two Doses of BI 474121 on Ketamine Induced Cognitive Deficits in Healthy Male Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 474121 | BI 474121 |
| DRUG | Placebo | Placebo |
| DRUG | Ketamine hydrochloride | Ketamine hydrochloride |
Timeline
- Start date
- 2022-11-07
- Primary completion
- 2023-06-05
- Completion
- 2023-06-20
- First posted
- 2022-07-11
- Last updated
- 2022-08-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05451095. Inclusion in this directory is not an endorsement.